HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 58.3%

Neg 0% Neu 0% Pos 58.3%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $90 to $95.